RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Circulating RI-001 Titer
The primary endpoint of this study was the mean fold titer increase from baseline to Day 18 in circulating serum anti-RSV neutralizing antibody following treatment with RI-001.
Study day 18
No
Upton Allen, MBBS
Principal Investigator
Division of Infectious Diseases, Hospital for Sick Children, Toronto, Ontario, Canada
United States: Food and Drug Administration
ADMA-001
NCT00632463
February 2008
May 2010
Name | Location |
---|---|
Fred Hutchinson Cancer Research Center | Seattle, Washington 98109 |
Rush University Medical Center | Chicago, Illinois 60612-3824 |
University of Rochester Medical Center | Rochester, New York 14642 |
Hackensack University Medical Center | Hackensack, New Jersey 07601 |
Children's National Medical Center | Washington, District of Columbia 20010-2970 |
All Children's Hospital | St. Petersburg, Florida 33701 |
Schneider Children's Hospital | New Hyde Park, New York 11042 |
Children's Medical Center of Dallas | Dallas, Texas 75235 |
University of California San Francisco | San Francisco, California 941104206 |
University of Colorado Health Sciences Center | Denver, Colorado 80262 |
New England Medical Center | Boston, Massachusetts |
Oregon Health and Science University | Portland, Oregon 97201 |
Johns Hopkins Medical Center | Baltimore, Maryland |
Cook Children's Medical Center | Fort Worth, Texas 76104 |
Seattle Children's Hospital and Regional Medical Center | Seattle, Washington 98105 |